BICO Group AB (publ) (BICO) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to BICO Q4 2025 report presentation. For the first part of the presentation, participants will be in listen-only mode. During the questions and answers session, participants are able to ask questions by dialing pound key five on their telephone keypad. Now I will hand the conference over to the speakers, CEO Maria Force and CFO Jacob Thordenberg. Please go ahead. Hello and welcome to BiCo Group's Q4 2025 earnings call. I'm Maria Fors, President and CEO and I will together with BiCo's CFO Jakob Thorndenberg present this year's end report. Here's today's agenda. I will open today's session by summarizing 2025 and also describe how BiCo serves the world's leading pharma and biotech companies with solutions that transform how labs operate, innovate and solve our customer challenges. Following that, I will summarize the full year 2025 as well as Q4 2025 and Jakob will then present the group's financial performance. We will then proceed and comment on our performance in the two business areas, Life Science Solutions and Lab Automation. I will also comment on our R&D pipeline with our ongoing product development efforts. Additionally, I will highlight product launches made at SLAS, the Society of Lab Automation and Screening Congress that took place last week in Boston. The session will conclude by highlighting our focus for 2026 before we open up for Q&A. When summarizing 2025, we can conclude that we finished the year on a strong note with double-digit organic sales growth in lab automation and a strengthened cash position. After the quarter in January 26, we successfully raised new capital, enabling investments to support further growth. 2025 has been a year of strategy execution. We have delivered on all key strategic initiatives and the impact is clear. A portf...